NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it will present new findings at the upcoming 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in San Diego. The presentations include Acumen’s recruitment strategies for its Phase 2 ALTITUDE-A ...

Core Viewpoint - Acumen Pharmaceuticals has entered into a collaboration with JCR Pharmaceuticals to develop an Enhanced Brain Delivery therapy targeting amyloid beta oligomers for Alzheimer's disease treatment [1][2][3] Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer's disease [1][13] - The lead program, sabirnetug (ACU193), is a humanized monoclonal antibody that selectively targets AβOs, which are linked to neurodegeneration in Alzheimer's disease [4][11] Collaboration Details - The collaboration aims to combine Acumen's AβO-targeted antibody expertise with JCR's blood-brain barrier-penetrating technology, J-Brain Cargo, to enhance therapeutic delivery to the brain [2][7] - Acumen has an exclusive option to develop up to two candidates from this collaboration, with preclinical data expected in early 2026 [7][10] Technology Insights - J-Brain Cargo technology utilizes receptor-mediated transcytosis to deliver drugs to the central nervous system, applicable to various therapeutic modalities [3][14] - JCR's technology has previously led to an approved therapy in Japan, demonstrating its efficacy and safety profile [3][14] Clinical Trials - Acumen is currently conducting the ALTITUDE-AD Phase 2 clinical trial, which has enrolled 542 patients with early Alzheimer's disease, with topline results expected in late 2026 [5][12] - The Phase 1 INTERCEPT-AD trial showed that sabirnetug was well-tolerated and demonstrated significant amyloid plaque reduction compared to placebo [4][5] Financial Terms - Under the collaboration agreement, JCR will receive an upfront payment and may earn additional payments based on development milestones and royalties from future sales [10]